Figure 2.

Targeting DDR-deficient PC with platinum and PARP inhibitors. (A) Cell viability after 72 hours of cisplatin treatment in PDCLs. The dotted line indicates that EC₅₀ in the most sensitive PDCL was approximately 15 times more sensitive than the most resistant PDCLs. (B) Boxplot of mean cisplatin EC₅₀ in PDCLS stratified by DDR status. The boxes represent the 95% confidence interval, and whiskers show the minimum and maximum range. P was calculated by using the Mann-Whitney test between the mean EC₅₀ in each group. (C) PARP inhibitor (BMN-637 and rucaparib) response in PDCLs. The dotted lines indicate the EC₅₀ between the most sensitive and most resistant PDCLs. P indicates the statistical difference between TKCC 10 (GPOL HRD test positive) and TKCC15 (DDR proficient) using nonlinear regression analysis. (D) PDX 2133 and (E) PDX 2179 (DDR deficient) treated with a panel of DNA-damaging agents and gemcitabine. The colored arrows indicate redosing of specific agents. M, mol/L.